Vaccinex (VCNX) announced that it will present new biomarker data that neoadjuvant treatment with pepinemab enhanced the clinical activity of immune checkpoint inhibitors in poorly immunogenic, HPV-negative, head and neck cancer, HNSCC. In a presentation at Society for Immunotherapy of Cancer’s Annual Meeting, SITC, on November 8th, Vaccinex will present data from the Phase 2 KEYNOTE-B84 study for treatment of recurrent and metastatic disease as well as an independent study evaluating neoadjuvant treatment of resectable HNSCC showing that pepinemab combination treatments appear to induce mature lymphoid aggregates correlating with clinical benefit within immunotherapy resistant tumor populations, including HPV-negative and PD-L1 low HNSCC.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCNX:
- Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
- Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
- Vaccinex files to sell 1.6M shares of common stock for holders
- Vaccinex announces exercise of warrants for $6.2M in gross proceeds
- Vaccinex Director Chrystyna Bedrij Stecyk Abruptly Resigns
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue